Clinical Trials Logo
  1. Home
  2. Menopausal Syndrome
  3. NCT05280028

HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness

Menopausal Syndrome Clinical Trial

Official title:
The Impact of Different Hormone Therapy Regimens on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness

Clinical Trial Summary

Therefore, the aim of this study is to assess the therapeutic effect on overactive bladder symptoms, sexual function, heart rate variability, arterial stiffness, atherosclerosis, sleep, and depression between tibolone and E2V/MPA. From the results, the investigators will compare the effect of tibolone versus E2V/MPA on overactive bladder symptoms, sexual function, autonomic function, arterial stiffness, atherosclerosis, sleep and depression.

Clinical Trial Description

Menopausal syndromes include overactive bladder symptom, autonomic symptoms, and even sexual dysfunction. Hormone therapy (HT) is widely used for controlling menopausal symptoms. Common HT for menopausal syndrome with intact uterus includes tibolone, estradiol valerate (E2V) 1mg & medroxyprogesterone acetate (MPA), and conjugated equine estrogens (CEE) & MPA. However, only a few literatures mentioned about the therapeutic effect of tibolone, but lack of comparison research about their therapeutic effect on overactive bladder symptoms, sexual function, heart rate variability, arterial stiffness, atherosclerosis, sleep and depression. The knowledge of the above therapeutic effects should be important for choosing a suitable medication. Therefore, the aim of this study is to assess the therapeutic effect on overactive bladder symptoms, sexual function, heart rate variability and arterial stiffness between tibolone and E2V/MPA. All female patients with intact uterus who underwent treatment for menopausal syndrome at Far Eastern Memorial Hospital from October 2021 will be included. An open-labeled, prospective, comparative study design will be used. HT included tibolone (2.5 mg/day) or E2V (1mg) & MPA (2.5 mg) per day. The enrolled women will be requested to complete the Greene climacteric scale, Urgency Severity Scale, Overactive Bladder Symptom Score, the International Prostate Symptom Score (IPSS), the Female Sexual Function Index (FSFI), the Pittsburgh Sleep Quality Index, Center for Epidemiological Studies Depression questionnaire, heart rate variability, arterial stiffness and atherosclerosis examinations at baseline, and 4 weeks (visit 2) and 12 weeks (visit 3) after treatment. From the results, the investigators will compare the effect of tibolone versus E2V/MPA on overactive bladder symptoms, sexual function, autonomic function, arterial stiffness, atherosclerosis, sleep and depression. Currently, there is no similar research as our current study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05280028
Study type Observational
Source Far Eastern Memorial Hospital
Contact Sheng-Mou Hsiao, MD
Phone +8868966700
Email smhsiao2@gmail.com
Status Recruiting
Phase
Start date February 7, 2022
Completion date December 31, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT01741974 - Study of Anti-atherosclerotic and Estrogen-like Activity of Karinat in Perimenopausal Women Phase 3
Not yet recruiting NCT05522621 - A Muticenter Clinical Study of Chinese Herbal Compound TJAOA102 in Alleviating Menopausal Syndrome Early Phase 1
Completed NCT01046643 - Early Menopause Hormone Treatment and Cognition N/A
Active, not recruiting NCT00694733 - Regulation of Cortisol Metabolism and Fat Patterning N/A
Completed NCT05759936 - 4-week Seaweed Supplementation on Menopause Symptoms and Psychological Wellbeing N/A
Completed NCT05266079 - Comparison Study for Perimenopausal Syndrome With Chinese Herbal Medicine N/A
Completed NCT04520542 - The Effect of Acupressure Application on Menopausal Symptoms N/A
Completed NCT02749747 - Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric Phase 3
Completed NCT01849172 - Effect and Safety of Electroacupuncture for Symptoms of Menopausal Transition N/A
Enrolling by invitation NCT03948269 - The Effect of Internet- and Mobile-based Group Treatment in Menopausal Women N/A
Recruiting NCT04031456 - Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients Phase 2/Phase 3
Recruiting NCT02294500 - Cohort Study to Evaluate Ovarian Function N/A
Completed NCT02467673 - Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy Phase 2
Completed NCT00289926 - Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms Phase 3
Recruiting NCT01698164 - Multi-centre Clinical Trial on Hormone Replacement Treatment in China Phase 4
Completed NCT05463081 - Clinical Trial of "Magic Gyno" Laser Device N/A
Completed NCT00933725 - Efficacy and Safety of Traditional Chinese Medicine Intervention for Women With Menopausal Syndrome Phase 3
Enrolling by invitation NCT02001402 - Chinese Health Investigation of Nurse Aging N/A
Recruiting NCT04726254 - The JULI Registry--Hemp and Cannabis Observational Registry
Completed NCT01931748 - A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome Phase 3